Type of non Hodgkin's lymphoma-Mantle cell lymphoma Posts on Medivizor
Navigation Menu

Type of non Hodgkin’s lymphoma-Mantle cell lymphoma Posts on Medivizor

Evaluating the effectiveness and safety of venetoclax with dose-adjusted EPOCH-R as initial therapy for patients with aggressive B-cell lymphoma.

Evaluating the effectiveness and safety of venetoclax with dose-adjusted EPOCH-R as initial therapy for patients with aggressive B-cell lymphoma.

Posted by on Sep 18, 2022 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of adding venetoclax (Venclexta) to a dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) regimen as initial therapy in patients with aggressive B-cell lymphoma. The data showed that venetoclax with dose-adjusted EPOCH-R was effective...

Read More

Evaluating response to SARS-CoV-2 vaccination in patients with blood cancers

Evaluating response to SARS-CoV-2 vaccination in patients with blood cancers

Posted by on Aug 26, 2022 in Non-Hodgkin lymphoma | 0 comments

In a nutshell The study aimed to investigate the rate of response (seroconversion) to SARS-Cov-2 vaccination in patients with blood cancers. This study concluded that seroconversion rates in these patients were significantly lower than that of healthy controls.   Some background The severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2)...

Read More

Evaluating the effectiveness and safety of mosunetuzumab for patients with relapsed/refractory non-Hodgkin lymphoma.

Evaluating the effectiveness and safety of mosunetuzumab for patients with relapsed/refractory non-Hodgkin lymphoma.

Posted by on Apr 3, 2022 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the effectiveness and safety of mosunetuzumab (RG7828) for the treatment of patients with relapsed or refractory (r/r) non-Hodgkin lymphoma (NHL). The data showed that mosunetuzumab resulted in long-lasting complete responses with manageable side effects for these patients. Some background NHL is cancer that...

Read More

Do patients with B-cell lymphoma respond properly to the Pfizer BioNTech COVID-19 vaccine?

Do patients with B-cell lymphoma respond properly to the Pfizer BioNTech COVID-19 vaccine?

Posted by on Sep 12, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study looked at the use and response of the Pfizer BioNTech COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma (NHL). It found that patients with NHL undergoing treatment with rituximab (Rituxan)/obinutuzumab (Gazyva) had a poorer immune response to this vaccine, compared to patients without...

Read More

Evaluating long-term effectiveness and safety of venetoclax patients with for non-Hodgkin lymphoma

Evaluating long-term effectiveness and safety of venetoclax patients with for non-Hodgkin lymphoma

Posted by on Jul 11, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This early study looked at the long-term results of the targeted treatment venetoclax (Venclexta) for patients with relapsed non-Hodgkin lymphoma (NHL). It found that venetoclax is a safe and effective treatment and that some patients have a durable response. Some background NHL is a group of cancers of a type of white blood...

Read More

Evaluating allogeneic stem cell transplantation for patients with mantle cell lymphoma

Evaluating allogeneic stem cell transplantation for patients with mantle cell lymphoma

Posted by on May 30, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the effectiveness of an allogeneic stem cell transplant (alloSCT) for patients with mantle cell lymphoma (MCL). The authors concluded that this treatment was effective for high-risk patients. Some background MCL is an aggressive type of non-Hodgkin lymphoma (NHL). Chemoimmunotherapy is the typical first-line...

Read More

Evaluating pirtobrutinib for the treatment on B cell leukemia/lymphoma

Evaluating pirtobrutinib for the treatment on B cell leukemia/lymphoma

Posted by on Apr 30, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study tested the safety and effectiveness of pirtobrutinib (LOXO-305) in the treatment of patients with B cell leukemia/lymphoma. The authors found that pirtobrutinib was safe and had promising effectiveness in these patients. Some background B cells are a type of cell of the immune system. Some lymphomas and leukemias such as...

Read More

Comparing the GDP and ICE regimens as salvage treatment for relapsed/refractory aggressive lymphoma

Comparing the GDP and ICE regimens as salvage treatment for relapsed/refractory aggressive lymphoma

Posted by on Jan 17, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the effectiveness and safety of GDP (gemcitabine, dexamethasone, and cisplatin) and ICE (ifosfamide, carboplatin, and etoposide) regimens as salvage therapy in patients with relapsed/refractory aggressive lymphoma. The data showed that both the GDP and ICE regimens are suitable options for relapsed/refractory...

Read More

Testing the safety and effectiveness of loncastuximab tesirine for the treatment of relapsed/refractory B-cell non-hodgkin lymphoma

Testing the safety and effectiveness of loncastuximab tesirine for the treatment of relapsed/refractory B-cell non-hodgkin lymphoma

Posted by on Dec 26, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study aimed to evaluate the safety and effectiveness of loncastuximab tesirine (LoT; Lonca) for the treatment of patients with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL). The study found that LoT was safe and had promising activity in these patients.  Some background B-NHL is a type of...

Read More

Evaluating bendamustine with ofatumumab, carboplatin and etoposide for relapsed/refractory aggressive non-Hodgkin lymphoma

Evaluating bendamustine with ofatumumab, carboplatin and etoposide for relapsed/refractory aggressive non-Hodgkin lymphoma

Posted by on Dec 20, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study aimed to investigate the combination of bendamustine (Treanda), ofatumumab (Arzerra), carboplatin (Paraplatin), and etoposide (Etopophos) in patients with relapsed/refractory aggressive non-Hodgkin lymphoma (NHL).   This study concluded that this combination was safe and effective in these...

Read More

Second stem cell transplant using reduced intensity conditioning for leukemia or lymphoma

Second stem cell transplant using reduced intensity conditioning for leukemia or lymphoma

Posted by on Oct 25, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study aimed to investigate the outcomes of a second hematopoietic stem cell transplant (HSCT) after reduced-intensity conditioning (RIC) for patients with leukemia or lymphoma.   This study concluded that this treatment path is feasible and a good treatment alternative for these patients.   Some background Allogenic...

Read More

Looking for participants to test an experimental immunotherapy for relapsed non-Hodgkin lymphoma

Looking for participants to test an experimental immunotherapy for relapsed non-Hodgkin lymphoma

Posted by on Oct 11, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study will evaluate the antibody therapy odronextamab for patients with relapsed B-cell non-Hodgkin lymphoma (NHL). The primary outcomes will be how many patients respond to treatment, and how many have a complete response (cancer no longer detectable).  The details For B-cell NHL which has relapsed (returned) after...

Read More
ABOUT USHOW IT WORKSBLOG NEWS PARTNERS CONTACT US PRIVACY POLICY TERMS OF USE
FROM OUR BLOG
LATEST NEWS
CONNECT WITH US
© 2022 Medivizor